The membrane-anchored ubiquitin ligase gp78 promotes degradation of misfolded endoplasmic reticulum (ER) proteins and sterolregulated degradation of HMG-CoA reductase. It was known previously that Ufd1 plays a critical role in ER-associated degradation (ERAD) together with Npl4 and VCP. The VCP-Ufd1-Npl4 complex recognizes polyubiquitin chains and transfers the ubiquitinated proteins to the proteasome. Here we show that Ufd1 directly interacts with gp78 and functions as a cofactor. Ufd1 enhances the E3 activity of gp78, accelerates the ubiquitination and degradation of reductase, and eventually promotes receptormediated uptake of low-density lipoprotein. Furthermore, we demonstrate that the monoubiquitin-binding site in Ufd1 is required for the enhancement of gp78 activity and that the polyubiquitin-binding site in Ufd1 is critical for a postubiquitination step in ERAD. In summary, our study identifies Ufd1 as a cofactor of gp78, reveals an unappreciated function of Ufd1 in the ubiquitination reaction during ERAD, and illustrates that Ufd1 plays a critical role in cholesterol metabolism.
INTRODUCTION
The endoplasmic reticulum (ER) is the major organelle for protein synthesis, folding, and assembly in the secretory pathway. The maturation of proteins in the ER is not a perfect process. Eukaryotic cells have evolved a highly conserved ER quality-control system, termed ER-associated degradation (ERAD), to prevent the accumulation of terminally misfolded proteins (Hampton, 2002) . ERAD is the pathway that directs misfolded polypeptides to proteasomal degradation, thereby protecting cells from the damage caused by the accumulation of these improperly folded proteins. The processes of ERAD include recognition of the ''lesion'' on misfolded proteins, polyubiquitination, dislocation from ER to cytosol, and delivery to the proteasome for destruction (Meusser et al., 2005; Tsai et al., 2002; Carvalho et al., 2006; Denic et al., 2006) . Recent studies have suggested that some of these steps are tightly coupled together (Neuber et al., 2005; Younger et al., 2006; Schuberth and Buchberger, 2005; Song et al., 2005b) . However, how these events in ERAD are organized has remained obscure.
Ubiquitin fusion degradation 1 (Ufd1) protein is one of the essential components of ERAD and plays a key role in the degradation of misfolded proteins (Johnson et al., 1995) . In most circumstances, Ufd1 forms a complex with Npl4 and the AAA ATPase VCP (also known as p97 or Cdc48) to transfer the ubiquitinated proteins to the proteasome (Meyer et al., 2000; Ye et al., 2001 Ye et al., , 2003 Bays and Hampton, 2002; Meyer et al., 2002) . Dislocation across the ER membrane into the cytoplasm is a process that requires energy. The VCP-Ufd1-Npl4 complex has been proposed to form a ring-like structure around the substrates and provides the driving force for dislocation (DeLaBarre and Brunger, 2003; Pye et al., 2007) . The COOH-terminal one-third portion of Ufd1 binds both Npl4 and VCP at different sites (Bruderer et al., 2004; Pye et al., 2007) . In addition, Ufd1 binds polyubiquitin chains via its NH 2 -terminal domain, and this binding is synergistically enhanced by VCP (Ye et al., 2003) . Deletion of the NH 2 -terminal domain of Ufd1 results in the blockage of ERAD (Ye et al., 2003) , indicating that the polyubiquitin binding of Ufd1 is required for ERAD. However, a recent structural study has revealed that the NH 2 -terminal domain of Ufd1 comprises two independent binding sites for mono-and polyubiquitin, respectively (Park et al., 2005) . These sites' individual functions in ERAD are largely unknown.
The enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase) catalyzes the reduction of HMG-CoA to mevalonate, a rate-limiting step in the synthesis of cholesterol (Goldstein and Brown, 1990) . The stability of HMG-CoA reductase is tightly regulated in cells: HMG-CoA reductase protein is degraded through ERAD pathway in the presence of high levels of sterol (Sever et al., 2003; Song et al., 2005a) . This is one of the regulatory pathways that cells employ to feedback control the synthesis of cholesterol . Mammalian HMG-CoA reductase has two distinct domains: the NH 2 -terminal membrane domain with eight transmembrane helices, and the COOH-terminal cytosolic domain that exerts all of the catalytic activity of the enzyme (Liscum et al., 1985; Roitelman et al., 1992) . The membrane domain of reductase mediates sterol-induced ubiquitination and degradation (Gil et al., 1985; Skalnik et al., 1988) . Our previous study determined that gp78, a membrane-anchored ubiquitin ligase, catalyzes the sterol-induced ubiquitination of HMG-CoA reductase (Song et al., 2005b) . gp78 interacts with VCP and a membrane protein, Insig-1 or -2. Sterol promotes reductase to bind to Insig-1/2 through its membrane domain, thereby forming a quadruple complex containing reductase, Insig-1/2, gp78, and VCP. gp78 catalyzes the ubiquitination of reductase at specific lysine residues (Sever et al., 2003) . After ubiquitination, gp78-associating VCP appears to mediate the degradation of reductase (Song et al., 2005b) .
To further understand the mechanism of ERAD of HMGCoA reductase stimulated by sterol, we utilized affinity purification coupled with mass spectrometry to identify gp78-interacting proteins, and our results revealed Ufd1. We show that Ufd1 directly binds to gp78, potentiates its E3 activity in vitro, increases ubiquitination and degradation of HMG-CoA reductase in vivo, and thereby regulates the receptor-mediated uptake of low-density lipoprotein (LDL). Mutation of the mono-but not the polyubiquitin-binding site in Ufd1 abolishes the enhancement of gp78 activity by Ufd1. In summary, the current results identify Ufd1 as a cofactor of gp78, reveal an unappreciated function of Ufd1 in the ubiquitination reaction during ERAD, and find that Ufd1 plays a critical role in cholesterol metabolism. Together with the previous findings on Ufd1, our results indicate that Ufd1 has a dual role in ERAD: increasing E3 activity and mediating the postubiquitination step.
RESULTS

Ufd1 Interacts with gp78
To identify proteins associated with gp78, we raised antibodies against the cytosolic domain of gp78. Affinitypurified anti-gp78 antibody was used to immunopurify the gp78 complex from the detergent-solubilized membrane fraction of HEK293 cells. Proteins eluted from anti-gp78-coupled beads were subjected to SDS-PAGE, visualized with colloidal blue staining, and identified by tandem mass spectrometry. Of the proteins we identified, VCP and UBE2G2 (also called Ubc7) have been previously shown to directly interact with gp78 Song et al., 2005b; Ballar et al., 2006; Zhong et al., 2004) , which demonstrates that the method we used is effective. One of these proteins, Ufd1, was chosen for further study in this report ( Figure 1A) .
To confirm the interactions between Ufd1 and gp78, we first performed a coimmunoprecipitation (coIP) experiment to detect the interaction between endogenous proteins. A detergent extract of CHO cells was subjected to IP with control or anti-gp78 antibodies followed by immunoblot. The results showed that endogenous Ufd1 coprecipitated with gp78 ( Figure 1B , top panel, lane 1) but was absent in the pellet fraction of the control IP (top panel, lane 2). We next carried out a coIP experiment to confirm Figure 1 . Identification of Ufd1 as a gp78-Associated Protein (A) gp78 complex was immunoprecipitated with anti-gp78-coupled agarose from HEK293 cells as described in Experimental Procedures. The eluted proteins were subjected to SDS-PAGE and stained with colloidal blue. Proteins identified by mass spectrometry are indicated. The results shown are representative of two independent experiments. (B) CHO-7 cells were harvested, lysed, and subjected to immunoprecipitation with antigp78 or anti-GFP (control). Aliquots of the supernatant and pellet (5-fold of the supernatant) fractions of immunoprecipitates were subjected to SDS-PAGE. Immunoblot (IB) analysis was carried out with the indicated antibodies. (C) CHO-7 cells were transfected with the indicated expression plasmids. Twenty-four hours after transfection, cells were harvested, lysed, and subjected to immunoprecipitation with anti-FLAG (against Ufd1). Immunoblot analysis was carried out with the indicated antibodies. The asterisk denotes a crossreactive band. Results shown in (B) and (C) are representative of three independent experiments. the complex formation of transfected Ufd1 and gp78. CHO cells were transfected with different combinations of expression constructs, and 24 hr after transfection, the cell lysate was prepared and subjected to IP with anti-FLAG-coupled agarose to pull down FLAG-Ufd1. gp78 was present in the pellet fraction of FLAG-Ufd1 IP ( Figure 1C, top panel, lane 6) . Notably, Hrd1, another membrane-anchored ubiquitin ligase bearing homology to gp78 (Nadav et al., 2003; Kikkert et al., 2004) , did not coprecipitate with FLAG-Ufd1, although the expression level of Hrd1 was similar to that of gp78 as shown in the supernatant fraction ( Figure 1C, third panel) . Taken together, these results indicate that both endogenous and transfected Ufd1 can form a complex with gp78.
Ufd1 Directly Interacts with the Middle Region of gp78 through Residues 258-275 Both gp78 and Ufd1 have been shown to interact with VCP directly (Zhong et al., 2004; Song et al., 2005b; Meyer et al., 2000) . To test the possibility that the gp78-Ufd1 interaction is indirectly bridged by VCP, we carried out coIP experiments using cells in which the expression of VCP was knocked down by RNA interference (RNAi). As shown in Figure S1 in the Supplemental Data available with this article online, Ufd1 still coprecipitated with gp78 regardless of VCP RNAi (lanes 3-4). Immunoblotting revealed that the expression of VCP protein was substantially reduced by RNAi ( Figure S1 ).
Next, to gain more insights on the gp78-Ufd1 interaction, the regions of gp78 and Ufd1 responsible for their interaction were mapped. A series of constructs encoding gp78 deletion mutants fused with Myc tags were cotransfected with FLAG-Ufd1 construct into CHO cells. The cell lysates were subjected to anti-Myc IP, and gp78 and Ufd1 were detected by immunoblot. Almost all gp78 fragments, except for D383-578 and D383-497, were capable of binding to Ufd1 ( Figure 2B ). The results, summarized in Figure 2A , indicate that Ufd1 binds to gp78 at the region between residues 383 and 497, which is different from the VCP-interacting motif (aa 614-643) (Figure 2A ) . Since the Ufd1-binding region in gp78 contains a Cue domain that usually binds to ubiquitin or E2 (Biederer et al., 1997; Kang et al., 2003; Prag et al., 2003) , we next tested the binding of this Cue domain to Ufd1, ubiquitin, and UBE2G2. As shown in Figure S2 , the separated Cue domain alone and its adjacent region (aa 383-456) can interact with Ufd1 individually, although the adjacent region shows stronger interaction, suggesting that more than one discrete binding site may be present in the aa 383-497 fragment. The Cue domain of gp78 alone efficiently binds to ubiquitin, but not to UBE2G2, consistent with the previous study by Chen et al. (2006) .
To identify the region of Ufd1 that interacts with gp78, we transfected a series of constructs encoding FLAGtagged Ufd1 deletion mutants together with gp78-Myc construct into CHO cells. The cell lysates were subjected to anti-FLAG IP, and gp78 and Ufd1 were detected by immunoblot. Our results showed that only the Ufd1 variants D215-302 and D258-275 could not bind to gp78 ( Figure 2D ). Collectively, the residues between 258 and 275 in Ufd1 are required for interaction with gp78 (summarized in Figure 2C ). This region in Ufd1 overlaps with the Npl4-binding site, but not the VCP-binding site (Bruderer et al., 2004) . Interestingly, Ufd1(D8-119) and Ufd1(D120-214) bind to gp78 better than full-length Ufd1 does ( Figure 2D ). It is possible that the deletion of these regions renders the gp78-binding site more readily accessible.
Next, we performed an in vitro GST pull-down assay to demonstrate the direct interaction between gp78 and Ufd1. We purified recombinant proteins from E. coli. First, GST, GST-gp78c (cytosolic domain of gp78), and GSTgp78c(D383-497) were immobilized on glutathione agarose, and their bindings to His 6 -Ufd1 were tested. As shown in Figure 2E , Ufd1 was capable of binding to the gp78c fragment (lane 3), but not to the gp78c(D383-497) fragment, which lacks the residues required for Ufd1 binding (lane 4). Similarly, Ufd1 directly bound gp78c in a concentration-dependent manner ( Figure 2F , lanes 3 and 4). However, Ufd1 lacking residues 258-275 failed to bind to gp78c ( Figure 2F , lanes 5 and 6). Taken together, these data indicate that Ufd1 directly binds to gp78, and their interacting sites have been identified.
Ufd1 Enhances the Ubiquitination and Degradation of HMG-CoA Reductase In Vivo
Our previous studies have shown that gp78 interacts with Insig-1 and -2 through its transmembrane domain (Song et al., 2005b) . Sterol promotes HMG-CoA reductase to bind Insig; thereby, gp78 is recruited, ubiquitinates reductase at specific lysines, and causes reductase to be degraded by the proteasome (Sever et al., 2003) . Two types of sterols are known to stimulate the ubiquitination and degradation of HMG-CoA reductase: the oxysterol 25-hydroxycholesterol (25-HC) and the cholesterol precursor lanosterol (Song et al., 2005a; Song and Bose-Boyd, 2004) .
The experiment of Figure 3A was designed to determine the effect of Ufd1 overexpression on sterol-regulated ubiquitination of HMG-CoA reductase. After transfection and sterol depletion, cells were treated with or without 25-HC in the presence of 10 mM MG132 (a proteasome inhibitor, to block protein degradation) for 3 hr. HMG-CoA reductase was then immunoprecipitated, and its ubiquitination was analyzed. In the absence of Ufd1, 25-HC modestly induced reductase ubiquitination ( Figure 3A , compare lanes 1 and 2). However, transfected Ufd1 dramatically enhanced 25-HC-induced ubiquitination of reductase ( Figure 3A , lane 4). Figure 3B shows that Ufd1 increased the ubiquitination of reductase in a concentration-and time-dependent manner.
We next performed a transfection experiment to determine the effect of Ufd1 on sterol-regulated degradation of HMG-CoA reductase. Consistent with previous reports, overexpressed reductase was not subject to sterolstimulated degradation ( Figure 3C , lanes 1 and 2). This is due to saturation of endogenous Insigs, as indicated by restoration of sterol-regulated degradation when Insig-1 was cotransfected ( Figure 3C , lanes 5 and 6) (Sever (E and F) GST, His 6 -fused Ufd1 fragments, and various GST-fused gp78 fragments were individually generated in bacteria, purified, and incubated at different combinations as indicated to perform GST pull-down assays. Samples were analyzed by immunoblot with the indicated antibodies or visualized by Coomassie blue staining. gp78c represents the cytosolic domain (aa 308-643) of gp78. The results shown in (B), (D), (E), and (F) are representative of three to four independent experiments. et al., 2003) . This degradation was significantly accelerated when Ufd1 was overexpressed (compare lanes 8 and 6), consistent with the notion that Ufd1 increases the ubiquitination of reductase.
The requirement of Ufd1 for sterol-dependent ubiquitination of endogenous HMG-CoA reductase was next addressed by reducing the expression of Ufd1 by RNAi. Human SV-589 fibroblast cells were transfected with control siRNA or siRNA against Ufd1. Sterol-depleted cells were treated with or without 25-HC in the presence of MG132 for 1 hr. HMG-CoA reductase was then immunoprecipitated, and its ubiquitination was analyzed. In control-transfected cells, 25-HC induced the ubiquitination of reductase ( Figure 3D , top panel, lane 2). When siRNA targeting Ufd1 was introduced into cells, the 25-HC-regulated ubiquitination of reductase was C in medium A containing 5% LPDS, 10 mM compactin, and 10 mM mevalonate. Cells were then switched to medium A containing 5% LPDS, 10 mM compactin, and 10 mM MG132 in the absence (À) or presence (+) of 1 mg/ml 25-hydroxycholesterol (25-HC). Following the indicated incubation time, cells were harvested, lysed, and subjected sequentially to immunoprecipitation with the indicated antibodies.
(C) CHO-7 cells were transfected and subsequently depleted of sterols as described in Figure 3A . Sterol-depleted cells were switched to medium A containing 5% LPDS and 10 mM compactin in the absence (À) or presence (+) of 1 mg/ml 25-HC plus 10 mM mevalonate. Following incubation for 5 hr at 37 C, cells were harvested, lysed, and subjected to immunoblot analysis with the indicated antibodies.
(D) SV-589 cells were transfected with the indicated siRNA as described in Experimental Procedures. Twenty-four hours later, the cells were depleted of sterols by incubating for 16 hr at 37 C in medium B containing 10% LPDS, 50 mM compactin, and 50 mM mevalonate. Cells were then switched to medium B containing 10% LPDS, 50 mM compactin, and 10 mM MG132 in the absence (À) or presence (+) of 0.1 mg/ml 25-HC as indicated. After 1 hr of incubation, cells were harvested, lysed, and subjected sequentially to immunoprecipitation with anti-HMG-CoA reductase antibody and immunoblot analysis with the indicated antibodies.
Results shown are representative of four independent experiments. (A and C) CHO-7 cells were transfected, treated as described in Figure 3A , harvested, lysed, and subjected sequentially to immunoprecipitation with anti-T7 (against HMG-CoA reductase) and immunoblot analysis with the indicated antibodies.
(B and D) CHO-7 cells were transfected, treated as described in Figure 3C , harvested, lysed, and subjected to immunoblot analysis with the indicated antibodies.
(E) E1, UBE2G2, Ufd1, Npl4, VCP, and GST-gp78c proteins were separately generated in bacteria and purified. In vitro ubiquitination assay was carried out at 37 C for 30 min as described in Experimental Procedures. The reactions were stopped by boiling and subjected to immunoblot assays or visualized by Coomassie blue staining.
dramatically decreased ( Figure 3D , top panel, compare lanes 4 and 2). Immunoblotting revealed that Ufd1 expression was substantially reduced by RNAi ( Figure 3D , third panel, lanes 3 and 4). As a control, the amount of actin protein in different samples was similar, regardless of sterol treatment or siRNA transfection ( Figure 3D , bottom panel, lanes 1-4).
gp78-and Ubiquitin-Binding Domains of Ufd1 Are Required for Its Function
To address whether the binding between Ufd1 and gp78 is required for the effect of Ufd1 on the ubiquitination and degradation of HMG-CoA reductase, we transfected cells with constructs encoding Ufd1 or Ufd1(D258-275), which does not bind to gp78. As shown in Figure 4A , the ubiquitination of reductase was increased by Ufd1 ( Figure 4A , lane 3), but not Ufd1(D258-275) ( Figure 4A , lane 4). Similarly, Ufd1, but not Ufd1(D258-275), accelerated sterolstimulated degradation of reductase ( Figure 4B , compare lanes 2, 4, and 6).
The aa 8-119 region of Ufd1 has been reported to constitute the ubiquitin-binding domains (Park et al., 2005) . We constructed Ufd1(D8-119) and tested it in transfection experiments. Ufd1(D8-119) blocked the ubiquitination and degradation of reductase stimulated by 25-HC when it was cotransfected with Insig-1 and reductase ( Figure 4C , lane 3; Figure 4D , lanes 3 and 4). However, Ufd1(D8-119&D258-275) lacking the gp78-binding site (aa 258-275) failed to block the ubiquitination and degradation of reductase ( Figure 4C , lane 4; Figure 4D , lanes 5 and 6). Taken together, these data indicate that binding to gp78 is a prerequisite for Ufd1 to regulate the sterol-regulated ubiquitination and degradation of reductase. Ufd1 that lacks the gp78-binding site exhibits the effect of loss of function.
Ufd1 Enhances the E3 Activity of gp78 In Vitro
A well-established function of Ufd1 is to escort ubiquitinated proteins to the proteasome for degradation (Bays and Hampton, 2002) . However, we observed that Ufd1 can enhance the ubiquitination of reductase in vivo. This raises the possibility that Ufd1 may enhance the intrinsic E3 activity of gp78 directly by their interaction. To exclude the postubiquitination activity of Ufd1 and test this possibility directly, we analyzed the effect of Ufd1 on the E3 activity of gp78 in an in vitro ubiquitination system containing purified recombinant E1, UBE2G2, gp78c, and ubiquitin. As shown in Figure 4E , gp78c catalyzed ubiquitin ladder formation in vitro (lane 1). The reaction was enhanced by Ufd1 protein in a concentration-dependent manner (Figure 4E, lanes 2-4) . In contrast, recombinant Npl4 and VCP had no effect on the ubiquitination reaction ( Figure 4E , lanes 5-10).
HERP is a short-lived ER-associated protein that interacts with gp78. The cytosolic domain of HERP (HERPc) can be efficiently ubiquitinated by gp78 in vitro (Li et al., 2007) . To further determine whether Ufd1 increases gp78-mediated substrate ubiquitination, we purified the HERPc protein and tested it in the in vitro ubiquitination assay. As shown in Figure 4F , Ufd1 itself had no effect (lane 3), but it greatly enhanced the polyubiquitination of HERPc protein in the presence of gp78c in vitro (compare lanes 2 and 1). Thus, our data clearly demonstrate that Ufd1 directly promotes ubiquitin ladder formation and substrate ubiquitination catalyzed by gp78.
The Monoubiquitin-Binding Site of Ufd1 Is Required to Enhance the E3 Activity of gp78 Previous work has illustrated that the ubiquitin-binding domain of Ufd1 encompasses the first 119 residues and is required for the dislocation process during ERAD (Park et al., 2005; Ye et al., 2003) . It has been proposed that Ufd1 binds to the polyubiquitin chains on ERAD substrates by this domain and further mediates the postubiquitination reaction (Ye et al., 2003) . However, recent structural studies of Ufd1 using NMR have revealed that Ufd1 has distinct binding sites for monoubiquitin and polyubiquitin chains within the first 119 residues (Walters, 2005; Park et al., 2005) . The functions of the ubiquitinbinding sites in Ufd1 are largely unknown. Since our results revealed a function of Ufd1 to activate gp78, we next tested the roles of both ubiquitin-binding sites in our ubiquitination and degradation assays.
Based on the identified mono-and polyubiquitinbinding sites in Ufd1 (Park et al., 2005) , we constructed Ufd1 mutants that carried mutations on the individual sites. Their effects on the ubiquitination of HMG-CoA reductase in intact cells were measured. As shown in Figure 5A , wild-type Ufd1 (Ufd1(WT)) significantly increased the ubiquitination of reductase (lane 3). The Ufd1 mutant carrying mutations on the monoubiquitinbinding site (Ufd1(MUB Mut)) decreased the sterolinduced ubiquitination of reductase ( Figure 5A, lane 4) . In contrast, the mutant Ufd1 lacking the polyubiquitinbinding site (Ufd1(PUB Mut)) dramatically increased the ubiquitination of reductase ( Figure 5A , lane 5), as Ufd1(WT) did ( Figure 5A, lane 3 ).
An in vitro ubiquitination assay was then carried out to measure the effects of the mutant Ufd1 proteins on the E3 activity of gp78. Similarly, Ufd1(WT) and Ufd1(PUB Mut) strongly enhanced the ubiquitination reaction in a concentration-dependent manner ( Figure 5B , lanes 2-4, 7, and 8), but Ufd1(MUB Mut) failed to increase the ubiquitination reaction ( Figure 5B , lanes 5 and 6). These data demonstrate that the monoubiquitin-binding site of Ufd1 is required for the enhancement of the E3 activity of gp78.
(F) In vitro ubiquitination reactions in which 0.3 mg HERPc-Myc and 0.3 mg/ml Ufd1 protein were applied were performed as described in Figure 4E . After 30 min of reaction, the mixtures were diluted, immunoprecipitated with anti-Myc (against HERPc), and immunoblotted with the indicated antibodies. Results shown are representative of three to four independent experiments.
We next tested the effects of these Ufd1 mutants on the sterol-regulated degradation of HMG-CoA reductase. Ufd1(WT) accelerated the sterol-induced degradation of reductase ( Figure 5C, lane 4) . Strikingly, this degradation was blocked by either Ufd1(MUB Mut) or Ufd1(PUB Mut) ( Figure 5C, lanes 6 and 8) . Taken together, these data indicate that Ufd1(PUB Mut) lacking the polyubiquitinbinding site enhances ubiquitination but blocks degradation of reductase, indicating that the polyubiquitin-binding site of Ufd1 is required for a postubiquitination step in ERAD of reductase.
Ufd1
Regulates the Cellular Uptake of LDL HMG-CoA reductase is the rate-limiting enzyme in the cholesterol synthesis pathway and is tightly regulated. When its activity or protein amount is decreased, cellular cholesterol concentration is downregulated and the compensatory sterol regulatory element-binding protein (SREBP) pathway is activated. The nuclear form of SREBP (nSREBP) is increased, and the expression of LDL receptor is in turn upregulated, which leads to a compensatory increase of cholesterol absorption (Brown and Goldstein, 1999) . Since Ufd1 plays important roles in the degradation of HMG-CoA reductase (Figures 3-5) , we hypothesized that overexpression of Ufd1 would accelerate reductase degradation, decrease cholesterol synthesis, increase nSREBPs, and ultimately enhance the uptake of LDL through elevating the expression of LDL receptor (Brown and Goldstein, 1999) . To test this hypothesis, we made a cell line stably overexpressing Ufd1. In this cell line, reductase protein was decreased ( Figure 6A , top panel) and nuclear SREBP-1 and -2 were increased (second and third panels). To test whether the activation of SREBPs causes a functional increase of LDL receptor, we performed LDL uptake assays. There was a remarkable increase in the intensity of intracellular fluorescence (fluorescently labeled LDL uptake) in Ufd1-overexpressing cells compared with control cells ( Figure 6B , red signal). Quantification revealed that the LDL uptake was increased by about 4-fold when Ufd1 was overexpressed. (A) CHO-7 cells were transfected, treated, and processed as described in Figure 3A , and immunoblots were performed with the indicated antibodies. MUB Mut, monoubiquitin-binding site mutant; PUB Mut, polyubiquitin-binding site mutant. (B) In vitro ubiquitination assay was carried out as described in Figure 4E , and the reaction mixtures were analyzed by immunoblot with the indicated antibodies. The asterisk denotes a degraded band. (C) CHO-7 cells were transfected, treated, and processed as described in Figure 3C , and immunoblots were performed with the indicated antibodies. The asterisk denotes a crossreactive band. Results shown are representative of three independent experiments. Similar results were also obtained from multiple independent cell clones stably overexpressing Ufd1 protein (data not shown).
To further exclude the variations of individual stable cell clones, we transfected CHO-7 cells with mock or FLAGUfd1-encoding plasmids. Following selection by G418, we obtained the cell mixture stably expressing Ufd1. The cell populations were then supplied with fluorescently labeled LDL (DiI-LDL) to analyze the uptake of LDL. As shown in Figure S3 , the intensity of intracellular fluorescence in cells stably expressing Ufd1 was much stronger than that in control cells.
Meanwhile, we measured LDL uptake in Ufd1-RNAi cells. Figure 6D shows that Ufd1 was efficiently knocked down by RNAi (compare lanes 2 and 1). In contrast to Ufd1-overexpressing cells, the uptake of fluorescently labeled LDL was dramatically decreased in Ufd1-RNAi cells ( Figure 6E, red signal) . This result is consistent with the data from the Ufd1 overexpression experiment and demonstrates that Ufd1 modulates the uptake of LDL through regulating the stability of reductase.
In summary, our data demonstrate that Ufd1 directly interacts with gp78 and functions as a cofactor. Through enhancing gp78 activity and mediating the postubiquitination step, Ufd1 increases the sterol-stimulated ubiquitination and degradation of HMG-CoA reductase, thereby upregulating the receptor-mediated clearance of LDL.
DISCUSSION
The Direct Interaction between gp78 and Ufd1 Previous studies have found that VCP is capable of binding to Ufd1 or gp78 (Zhong et al., 2004; Meyer et al., 2000; Song et al., 2005b) . Here, we provide strong evidence showing that the direct interaction between Ufd1 and gp78 is not bridged by VCP. First, the Ufd1-binding region (aa 383-497) in gp78 is different from the VCP-interacting motif (VIM, aa 614-643) Zhong et al., 2004) . A gp78 mutant without the VIM can still bind to Ufd1 ( Figure 2B ). Second, gp78 and VCP bind to Ufd1 at different sites ( Figure 2C ) (Bruderer et al., 2004) . A mutant of Ufd1 lacking the VCP-binding site can still interact with gp78 ( Figure 2D) . Third, the binding of endogenous gp78 to Ufd1 is unaffected by VCP RNAi ( Figure S1 ). Finally, Ufd1 directly binds to gp78, as demonstrated by in vitro GST pull-down assays in which VCP was absent ( Figures  2E and 2F) . These results exclude the possibility that VCP mediates the interaction between Ufd1 and gp78.
We have mapped the interacting regions on gp78 and Ufd1 by coIP and in vitro pull-down assays. Interestingly, the gp78-binding region in Ufd1 (residues 258-275) overlaps with the reported Npl4-binding site (Bruderer et al., 2004) . The VCP-Ufd1-Npl4 complex has been widely studied and has been shown to play an important role in ERAD. Therefore, we performed further experiments to test the competition between Npl4 and gp78 for Ufd1 binding. The results showed that gp78 and Npl4 bind to Ufd1 in a mutually exclusive manner ( Figure S4 ). Taken together, our data suggest that Ufd1 binds to gp78 by itself and that the gp78-activating function of Ufd1 is independent of Npl4 and VCP. Furthermore, it is possible that Npl4 and VCP may also conduct important functions by themselves.
Recently, Ballar et al. (2006) showed that VCP cannot bridge the interaction between gp78 and Ufd1. This finding is consistent with our finding that gp78 directly binds to Ufd1. However, in their study, Ballar et al. did not detect the association between gp78 and Ufd1. We reason that this discrepancy most likely reflects differences in the ratio of gp78 to Ufd1 used in two study systems. In the present work, we detected the interaction between endogenous gp78 and Ufd1, as well as that between the cotransfected proteins ( Figure 1; Figure 2 ; Figure S1 ). However, Ballar et al. used cells overexpressing gp78 and one of its substrates, CD3d. Therefore, endogenous Ufd1 may not be sufficient to bind both endogenous and exogenous gp78. This may also explain their observation that Ufd1 is dispensable for the degradation of CD3d in cells overexpressing gp78 but required for that in cells expressing endogenous levels of gp78.
Ufd1 Is a Cofactor of the Ubiquitin Ligase gp78
Ubiquitination is carried out through the sequential actions of three types of enzymes: the ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s). Ubiquitin is first covalently conjugated to a reactive cysteine residue of E1 (E1-Ub) and is then transferred to a catalytic cysteine of E2 (E2-Ub). Finally, E3 facilitates the transfer of ubiquitin from E2-Ub to a lysine residue on the substrate (or ubiquitin) (Pickart, 2001; Hershko et al., 2000) . This reaction can be repeated several times to form polyubiquitin chains. The substrate specificity is usually determined by E3. Occasionally, a specialized E3 ubiquitin ligase, E4 enzyme, elongates ubiquitin chains of oligoubiquitinated proteins to generate polyubiquitin conjugates from oligoubiquitinated precursors (Hoppe, 2005) .
Interestingly, Ufd1 significantly increases polyubiquitination in vivo and in vitro (Figure 3 and Figure 4) . What is the mechanism of Ufd1 in these events? One possibility is that Ufd1 works as an E4 that elongates the ubiquitin chains initiated by gp78. However, Ufd1 does not catalyze the formation of polyubiquitin chains by itself in vitro ( Figure 4F and data not shown). This piece of evidence suggests that Ufd1 is not an E4. On the other hand, gp78 directly interacts with Ufd1 ( Figure 1 and Figure 2) , and the enhancement of gp78-catalyzed polyubiquitination by Ufd1 is dependent on their interaction (Figure 4) , indicating that Ufd1 functions as a cofactor of gp78.
There are two main classes of cofactors of E3. In some cases, the cofactors help to recruit substrates. These cofactors bind E3 and substrates simultaneously. For example, Cdc20 bridges the E3 anaphase-promoting complex to its substrates, including cyclin B (Yu, 2002; Hershko, 1999) . The other class of cofactors function directly to increase the intrinsic activity of their interacting E3. They do not necessarily bind substrates directly. For instance, as Mdm2's cofactor, Daxx is found to enhance the E3 activity of Mdm2 (Tang et al., 2006) . In our case, Ufd1 directly increases the activity of gp78, and this effect is dependent on its monoubiquitin-binding site ( Figure 5 ). Studying whether Daxx binds monoubiquitin and whether this binding is required for its function will be interesting and will provide further insights.
During the reviewing of this paper, Li et al. (2007) published their study showing that gp78 first catalyzes formation of a polyubiquitin chain on UBE2G2 and then transfers the preassembled ubiquitin chain to a substrate. As a cofactor, Ufd1 can theoretically be involved in either of these steps. However, the data in Figure 4E show that Ufd1 enhances ubiquitin ladder formation in a substrate-free system in vitro, suggesting that Ufd1 may promote the first step in gp78-catalyzed reactions. We further tested the effect of Ufd1 on the polyubiquitin assembly on E2 and found that Ufd1 dramatically enhanced this assembly in a concentration-dependent manner ( Figure S5, lanes 1  to 3) . Therefore, our data support the notion that Ufd1 facilitates gp78 in catalyzing the polyubiquitin chain formation on UBE2G2.
The Mechanisms for Ufd1 Enhancing the E3 Activity of gp78 How does Ufd1 increase the E3 activity of gp78? One possibility is that Ufd1 helps gp78 to recruit E2-Ub. In the ubiquitin ligation reaction, the E3 enzyme utilizes the E2-Ub conjugate as a ubiquitin donor (Hershko et al., 2000; Pickart, 2001) . Previous studies have demonstrated that UBE2G2 is the E2 for gp78 (Fang et al., 2001; Chen et al., 2006) . The G2BR domain of gp78 (Figure 2A ) is responsible for UBE2G2 binding . Meanwhile, the monoubiquitin-binding site of Ufd1 interacts with ubiquitin. Therefore, UBE2G2-Ub may bind gp78-Ufd1 at these two different sites at the same time. This bivalent interaction may synergistically increase the affinity of UBE2G2-Ub to the gp78-Ufd1 complex. Consistently, both monoubiquitin-and gp78-binding sites in Ufd1 are required for the enhancement of gp78 activity (Figure 4 and Figure 5) .
Recently, there have been significant discoveries showing that Cdc48 (the yeast homolog of VCP) associates with Ufd2, an E4, to accelerate substrate ubiquitination and degradation during ERAD (Richly et al., 2005; Rumpf and Jentsch, 2006; Koegl et al., 1999) . It was found that Ufd2 is recruited to the ERAD substrates by the Cdc48-Ufd1-Npl4 complex through its direct interaction with Cdc48 and further polyubiquitinates the substrates, which eventually leads to proteasomal degradation (Koegl et al., 1999) . Although we have demonstrated that Ufd1 directly enhances the E3 activity of gp78 in vitro (Figures 4E and 4F;  Figure 5B ; Figure S5) , it is still possible that Ufd1 brings VCP-Ufd2 to the gp78 complex, which leads to the increasing of reductase ubiquitination in intact cells. If this is the case, reducing Ufd1 should diminish gp78-VCP interaction, and knocking down VCP should attenuate the ubiquitination of HMG-CoA reductase. To test this hypothesis, we first detected the gp78-VCP interaction by coIP upon Ufd1 RNAi. Our results showed that the VCP protein coimmunoprecipitated with gp78 was unaffected by reducing Ufd1 level ( Figure S6A ), indicating that Ufd1 does not bring VCP to gp78. Consistent with the notion that gp78 and Ufd1 bind VCP in a mutually exclusive manner , the VCP and Ufd1 proteins may interact with gp78 independently. Next, we analyzed the sterol-regulated ubiquitination of reductase after knocking down VCP by RNAi. As shown in Figure S6B , the ubiquitination of reductase was similar in the presence or absence of VCP. Taken together, our results do not support the hypothesis that Ufd1 enhances the ubiquitination of reductase in vivo by recruiting VCP-Ufd2.
It has been demonstrated in yeast that Cdc48 is capable of recruiting different cofactors (including Ufd2, Ufd3, and Otu1) to modulate the ubiquitination status of its substrates and determine their destinations (Rumpf and Jentsch, 2006) . However, it is currently unknown how the central role of Cdc48 in ERAD is regulated under physiological conditions. Substrate selectivity may exist, and VCP is possibly involved in the ERAD of unfolded proteins other than sterol-regulated degradation of HMG-CoA reductase.
Dual Functions of Ufd1 in the ERAD of HMG-CoA Reductase There are two ubiquitin-binding sites in Ufd1: the monoand polyubiquitin-binding sites (Park et al., 2005) . Mutation of the monoubiquitin-binding site blocks both the ubiquitination and degradation of HMG-CoA reductase. On the other hand, mutation of the polyubiquitin-binding site enhances the ubiquitination but blocks degradation of reductase ( Figure 5 ).
According to our results, we propose a model illustrating the key functions of Ufd1 in the sterol-induced ERAD of HMG-CoA reductase, depicted in Figure 7 . The process is initiated by the sterol-promoted binding between reductase and Insig in the membrane, which recruits the Insigassociated E3 gp78. gp78 catalyzes the ubiquitination of reductase at specific lysine residues. Ufd1 is also brought into this complex by its interaction with gp78 and performs its first role here, enhancing the E3 activity of gp78 through monoubiquitin binding. After ubiquitination, the modified reductase is degraded by the proteasome. At this step, Ufd1 plays its second role, mediating the postubiquitination step that is dependent on the polyubiquitin-binding site. Therefore, Ufd1 plays a dual role in the sterolregulated degradation of reductase.
As an ER membrane-anchored ubiquitin ligase, gp78 mediates not only the sterol-regulated degradation of HMG-CoA reductase but also the degradation of other substrates, such as misfolded proteins. Our results reveal that Ufd1 is a cofactor of gp78 and plays a dual role in sterol-induced ERAD of HMG-CoA reductase. We further found that Ufd1 also accelerates the degradation of Insig-1 (Figure S7 ), another substrate of gp78 (Lee et al., Sterol stimulates the ER-associated degradation of HMG-CoA reductase by promoting the binding between reductase and the Insiggp78-VCP complex. Through direct interaction with gp78, Ufd1 participates in this process and plays a dual role: (1) increasing the ubiquitination reaction that requires the monoubiquitin-binding site in Ufd1, and (2) accelerating the postubiquitination step that is dependent on the polyubiquitin-binding site in Ufd1. Mutation of either the mono-or polyubiquitin-binding site in Ufd1 can block the degradation of reductase. 2006). It is possible that Ufd1 plays similar roles in the ERAD of other gp78 substrates, including CD3d (Fang et al., 2001) , ApoB-100 (Liang et al., 2003) , and a-1-antitrypsin . The direct interaction between gp78 and Ufd1 ensures effective ubiquitination and couples the ubiquitination step to the postubiquitination step. This discovery represents a configuration that assures the efficiency of the ERAD process.
Upregulation of Ufd1 May Be Beneficial for Hypercholesterolemia Patients
Cardiovascular disease is highly correlated with elevated level of plasma LDL cholesterol. The most common treatment for elevated cholesterol levels in humans is a group of drugs called statins that competitively inhibit the enzyme activity of HMG-CoA reductase. The inhibition of reductase activity by statins results in depletion of liver cholesterol, which promotes the maturation of nSREBPs. nSREBPs in turn activate transcription of the LDL receptor gene, thereby increasing receptor-mediated clearance of LDL (Brown and Goldstein, 1999) . At the same time, statins elevate the amount of HMG-CoA reductase, which becomes progressively harder to inhibit (Kita et al., 1980; Singer et al., 1984) .
This compensatory increase of reductase can be reduced by accelerating its degradation. Our research on the mechanism of sterol-regulated degradation of reductase provides important insights and potential drug targets for designing more effective therapies. We have demonstrated that elevating the expression of Ufd1 decreases levels of reductase and eventually causes an increase of the receptor-mediated uptake of LDL. Thus, Ufd1 and its interaction with gp78 may present attractive targets when developing new cholesterol-lowering therapies. Importantly, we have found that the binding of Ufd1 to gp78 is significantly potentiated by sterol and mevalonate ( Figure S8 ). The mechanism of this regulated interaction is currently under intensive investigation.
In conclusion, we have elucidated that Ufd1 directly binds to gp78 and potentiates its E3 activity toward HMG-CoA reductase, therefore regulating the receptormediated uptake of LDL. In addition, as a cofactor of gp78, Ufd1 has a dual role in gp78-promoted ERassociated degradation: increasing E3 activity that is dependent on the monoubiquitin-binding site and mediating the postubiquitination step that requires the polyubiquitin-binding site in Ufd1.
EXPERIMENTAL PROCEDURES
A complete description of materials, plasmids, cell culture, primary antibodies, recombinant protein purification, and other methods is available in the Supplemental Experimental Procedures.
Coimmunoprecipitation
Cells were harvested and lysed in 0.5 ml of PBS containing 0.1% NP-40 (v/v), 5 mM EDTA, 5 mM EGTA, 20 mM leupeptin, 25 mg/ml ALLN, 5 mg/ml pepstatin A, and 2 mg/ml aprotinin and clarified by centrifugation at 100,000 3 g for 10 min at 4 C. Immunoprecipitation with antibody-coupled agarose beads was carried out as described previously (Sever et al., 2003) .
GST Pull-down Assay GST fusion proteins were immobilized on glutathione agarose beads; blocked with PBS containing 0.1% NP-40 (v/v), 5 mM EDTA, 5 mM EGTA, 20 mM leupeptin, 25 mg/ml ALLN, 5 mg/ml pepstatin A, and 2 mg/ml aprotinin plus 5% nonfat milk; and incubated with the indicated proteins for 2 hr at 4 C. After washing five times, the bound proteins were dissolved in SDS sample buffer, separated by SDS-PAGE, and subjected to immunoblot assays.
In Vitro Ubiquitination Assay Standard ubiquitination reactions were performed in 100 ml volume containing 25 mM HEPES (pH 7.4), 10 mM NaCl, 3 mM MgCl 2 , 0.05% Triton X-100, 0.5 mM DTT, 3 mM Mg-ATP, 3 mg E1, 0.3 mg UBE2G2, 10 mg ubiquitin (Ub) or FLAG-Ub, 0.3 mg cytosolic domain of gp78 (gp78c, aa 308-643), and the indicated concentration of various Ufd1 proteins or HERPc protein. Reaction mixtures were incubated at 37 C for the indicated time.
LDL Uptake Assays
Cells grown on coverslips were incubated with medium A containing 5% LPDS and 10 mg/ml of fluorescently labeled LDL (DiI-LDL) (Invitrogen) for 2 hr, washed, and fixed in 4% paraformaldehyde in PBS for 20 min at room temperature. The cells were subsequently washed in PBS, and nuclei were stained with Hoechst. Intracellular fluorescent dye was detected by a 403 objective on an Olympus BX51 microscope. Images were acquired at identical exposure times and camera settings and quantified using Image-Pro Plus software. The total fluorescence intensity was divided by the number of cells in the same field to give the average intensity. The average intensity of control cells was defined as 100%. 
Supplemental Data
